A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

被引：0
|
作者：
I M E Desar
J N H Timmer-Bonte
D M Burger
W T A van der Graaf
C M L van Herpen
机构：
[1] Radboud University Nijmegen Medical Centre,Department of Medical Oncology 452
[2] Radboud University Nijmegen Medical Centre,Department of Clinical Pharmacy
来源：
British Journal of Cancer | 2010年 / 103卷
关键词：
phase I; sorafenib; sirolimus; tyrosine kinase inhibitor; mTOR inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1637 / 1643
页数：6
相关论文
共 50 条
  • [1] A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
    Desar, I. M. E.
    Timmer-Bonte, J. N. H.
    Burger, D. M.
    van der Graaf, W. T. A.
    van Herpen, C. M. L.
    BRITISH JOURNAL OF CANCER, 2010, 103 (11) : 1637 - 1643
  • [2] A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
    Hegde, Aparna
    Jayaprakash, Priyamvada
    Couillault, Coline A.
    Piha-Paul, Sarina
    Karp, Daniel
    Rodon, Jordi
    Pant, Shubham
    Fu, Siqing
    Dumbrava, Ecaterina E.
    Yap, Timothy A.
    Subbiah, Vivek
    Bhosale, Priya
    Coarfa, Cristian
    Higgins, Jack P.
    Williams, Eric T.
    Wilson, Thomas F.
    Lim, JoAnn
    Meric-Bernstam, Funda
    Sumner, Elizabeth
    Zain, Hira
    Di Nguyen
    Nguyen, Ly M.
    Rajapakshe, Kimal
    Curran, Michael A.
    Hong, David S.
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3050 - 3060
  • [3] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [4] Phase I dose-escalation trial evaluating the safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors
    Awada, A.
    Gil, T.
    Whenham, N.
    Vanhamme, J.
    Mancini, I.
    Besse, T.
    Brendel, E.
    Loembe, B.
    Piccart, M.
    Hendlisz, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 39 - 39
  • [5] A phase I dose-escalation study to evaluate pharmacokinetics, safety and tolerability of ACT001 in patients with advanced glioma.
    Shi, Yehui
    Bai, Guiying
    Wang, Peng
    Cai, Dongpo
    Chen, Yue
    Wang, Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors
    Gordon, Michael S.
    Springett, Gregory M.
    Su, Yungpo Bernard
    Ould-Kaci, Mahmoud
    Wind, Sven
    Zhao, Yihua
    LoRusso, Patricia M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1479 - 1491
  • [7] The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
    Yonemori, Kan
    Shimizu, Toshio
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Kitano, Shigehisa
    Sato, Jun
    Shimomura, Akihiko
    Shibaki, Ryota
    Suri, Ajit
    Kase, Yoichi
    Sumino, Shuuji
    Tamura, Kenji
    Yamamoto, Noboru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (05) : 693 - 699
  • [8] A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
    de Braud, F.
    Cascinu, S.
    Spitaleri, G.
    Pilz, K.
    Clementi, L.
    Liu, D.
    Sikken, P.
    De Pas, T.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2341 - 2346
  • [9] A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours
    Tolcher, A. W.
    Falchook, G.
    Bendell, J. C.
    Ungar, D.
    Boni, J.
    Chao, G.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2019, 30 : 176 - +
  • [10] A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer.
    Leong, S.
    Camidge, R.
    Eckhardt, G.
    Basche, M.
    Musib, L.
    Darstein, C.
    Thornton, D.
    Britten, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 91S - 91S
12345